

FOR IMMEDIATE RELEASE



Bee Vectoring Technologies Announces Go-To-Market Partnership Developments in North Africa and Middle East Regions

Mississauga, ON Canada and Sacramento, CA USA (July 24, 2024) – Bee Vectoring Technologies International Inc. (the “Company” or “BVT”) (CSE: BEE) (OTCQB: BEVVF) (CVE:BEE) is pleased to announce progress into markets in North Africa and the Middle East through strategic partnerships with leading, locally-connected agribusinesses in four key countries to commercialize the Company’s proprietary bee vectoring system and biological control agent *Clonostachys rosea* strain CR-7 (CR-7).

“These partnerships are at the core of our strategy for quickly scaling business,” said Ashish Malik, CEO of BVT. “Leveraging established local channels and using embedded sales teams is an incredibly cost-efficient way to access more of the market, fast.”

BVT continues to progress its strategic go-to-market collaborations in Turkey, Azerbaijan, Morocco and Israel.

In Turkey, the partnership is with BioGlobal: earlier this year, they ran demonstration trials with Turkey’s Ministry of Agriculture. The trial clearly showed that the BVT bee vectoring system, used with bumblebees and a third-party microbe, is incredibly effective in precisely delivering a beneficial microbe to greenhouse tomatoes.

“The trials were extremely successful,” said Christoph Lehnen, BVT Business Manager for Europe, Africa and the Middle East. “So much so that Turkey’s Ministry of Agriculture has requested an official protocol be developed by the country’s research institutes to trial *Clonostachys rosea* strain CR-7, BVT’s proprietary biological control agent.”

Once the protocol is secured, BioGlobal will proceed with registration trials for CR-7 in Turkey, then move forward with full-country registration. BVT is also collaborating with BioGlobal in Azerbaijan, where registration could be secured in as little as a year.

In Morocco, BVT has had successful trials on tomato crops. With the resulting strong data, applying for country registration is the next step. BVT will work with Groupe SAOAS on the submission which is planned to be timed alongside the submission to the European Union

In Israel, trials are being conducted with Lidorr Elements, a leading crop protection expert in the Israeli market. Lidorr Elements has commenced trials of CR-7 on almonds using the Company’s bee vectoring system for bumblebees, comparing it with traditional spray applications. Trials on strawberry and tomato crops are planned next.

The next step is registering BVT’s technology and selling it to local growers. This is the plan for the other three countries as well.

“These are strategic countries for BVT to fast track to market,” continued Mr. Lehnen. “Pollinating crops with bees are already a regular agriculture industry practice in these parts of the world. The four countries combined use more than 600,000⁽¹⁾ commercial bee hives each year.”

BVT’s addressable market in the four key countries includes 157,600 hectares of key crops grown. This includes an estimated 106,500 hectares of covered tomatoes, cherries and berries in Turkey; 8,100 hectares of covered tomatoes, covered apricots and berries in Azerbaijan; 22,000 hectares of covered tomatoes and berries in Morocco; and 31,000 hectares of almonds, tomatoes, peppers, berries, peaches and avocados in Israel.⁽²⁾

⁽¹⁾ Source: BVT estimate

⁽²⁾ Source: BVT sourced from information from collaboration partners and country statistics.

About [Bee Vectoring Technologies International Inc.](#)

BVT, an agriculture technology company, is a market disruptor with a significant global market opportunity in the \$240 billion crop protection and fertilizer market. BVT has pioneered a natural precision agriculture system that replaces chemical pesticides and wasteful plant protection product spray applications by delivering biological pesticide alternatives to crops using commercially grown bees. BVT’s award-winning technology, precision vectoring, is completely harmless to bees and allows minute amounts of naturally-derived pesticides (called biologicals) to be delivered directly to blooms, providing improved crop protection and yield results than traditional chemical pesticides – and improving the health of the soil, the microbiome and the environment. Currently, BVT has over 55 granted patents, many more patents pending in all major agricultural countries worldwide and has US EPA registration of its Vectorite™ with CR-7 (EPA Registration No. 90641-2) for sale as a registered biological fungicide for use on the labeled crops.

Additional information can be viewed at the Company’s website www.beevt.com. To receive regular news updates from the Company, subscribe at www.beevt.com/newsletter.

BVT Company Contact:

Ashish Malik, President & CEO, BVT

info@beevt.com

BVT Investor Contacts:

Babak Pedram

Virtus Advisory Group

Tel: 416-646-6779

bpedram@virtusadvisory.com

The CSE has neither approved nor disapproved the contents of this press release. The CSE does not accept responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company, "annual revenue potential", are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available

to the Company, and are subject to certain risks, uncertainties and assumptions, including: planted acres, selling price of competitive chemical pesticides and the US to Canadian dollar exchange rate. Material factors or assumptions were applied in providing forward-looking information. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include changes in law, competition, litigation, the ability to implement business strategies and pursue business opportunities, state of the capital markets, the availability of funds and resources to pursue operations, new technologies, the ability to protect intellectual property rights, the ability to obtain patent protection for products, third-party intellectual property infringement claims, regulatory changes affecting products, failing research and development activities, the ability to reach and sustain profitability, dependence on business and technical experts, the ability to effectively manage business operations and growth, issuance of debt, dilution of existing securities, volatility of publicly traded securities, potential conflicts of interest, unlikelihood of dividend payments, the potential costs stemming from defending third-party intellectual property infringement claims, the ability to secure relationships with manufacturers and purchasers, as well as general economic, market and business conditions, as well as those risk factors discussed or referred to in the Company's Filing Statement dated August 14, 2020, filed with the CSE and securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. All figures are in Canadian dollars.